Intraepithelial T cells and tumor proliferation: Impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer

Cancer

Volumn 115, Issue 13, 2009, Pages 2891-2902

  Adams, Sarah F ^a   Levine, Douglas A ^b   Cadungog, Mark G ^a   Hammond, Rachel ^a   Facciabene, Andrea ^a   Olvera, Narciso ^b   Rubin, Stephen C ^a   Boyd, Jeff ^c   Gimotty, Phyllis A ^a   Coukos, George ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d 1315 BRB II/III ^*  (United States)

Author keywords

Ovarian cancer; Surgical cytoreduction; T cells; Tumor proliferation

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; KI 67 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MITOSIS; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYSTADENOMA, SEROUS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; KI-67 ANTIGEN; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 67649624673     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24317     Document Type: Article

References (42)

1. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol. 2003;21:3488-3494. (Pubitemid 46594082)
2. Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627. (Pubitemid 47372600)
3. Winter WE III, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26:83-89.
4. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974-979, discussion 79-80. (Pubitemid 24157907)
5. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;47:159-166. (Pubitemid 23001322)
6. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64:9-12. (Pubitemid 27026949)
7. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278-287. (Pubitemid 29118182)
8. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2007;106:69-74.
9. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77-85. (Pubitemid 43755507)
10. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083-1090. (Pubitemid 44821338)
11. Bookman MA. First-line randomized trials: revisiting the Ptolemaic universe. Int J Gynecol Cancer. 2008;18(suppl 1):47-52.
12. Ledermann JA. Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2008;18(suppl 1):53-58.
13. Mobus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007;25:4187-4193. (Pubitemid 47548557)
14. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
15. McMenamin ME, O'Neill AJ, Gaffney EF. Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival. Mol Pathol. 1997;50:242-246. (Pubitemid 27475773)
16. Anttila M, Kosma VM, Ji H, et al. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol. 1998;16:2591-2600. (Pubitemid 28363021)
17. Sahin AA, Ro JY, el-Naggar AK, et al. Tumor proliferative fraction in solid malignant neoplasms. A comparative study of Ki-67 immunostaining and flow cytometric determinations. Am J Clin Pathol. 1991;96:512-519.
18. Henriksen R, Strang P, Backstrom T, Wilander E, Tribukait B, Oberg K. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res. 1994;14(2B):603-608. (Pubitemid 24172179)
19. Kaern J, Aghmesheh M, Nesland JM, et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer. 2005;15:1014-1022.
20. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-213. (Pubitemid 36077915)
21. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538-18543. (Pubitemid 43011261)
22. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104:3360-3365. (Pubitemid 46364164)
23. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10: 942-949. (Pubitemid 39273735)
24. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056. (Pubitemid 46657407)
25. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134. (Pubitemid 46596766)
26. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006; 103:559-564.
27. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2008;108:415-420. (Pubitemid 351174290)
28. Santin AD, Hermonat PL, Ravaggi A, et al. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest. 2001;51:254-261. (Pubitemid 32620125)
29. Kooi S, Freedman RS, Rodriguez-Villanueva J, Platsoucas CD. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res. 1993;12:429-437. (Pubitemid 24007548)
30. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast, ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A. 1995;92:432-436.
31. Dadmarz RD, Ordoubadi A, Mixon A, et al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am. 1996;2:263. (Pubitemid 126476658)
32. Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol. 2000;96:422-430. (Pubitemid 30674287)
33. Freedman RS, Platsoucas CD. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat Res. 1996;82:115-146.
34. Blegen H, Einhorn N, Sjovall K, et al. Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. Int J Gynecol Cancer. 2000;10:477-487. (Pubitemid 32066631)
35. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25:5864-5874. (Pubitemid 44453442)
36. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138-1145. (Pubitemid 28380718)
37. Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch. 2005;446:10-14. (Pubitemid 40179150)
38. Buckowitz A, Knaebel HP, Benner A, et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer. 2005;92:1746-1753. (Pubitemid 40756487)
39. Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 2008;109:215-219.
40. Sabbatini P, Odunsi K. Immunologic approaches to ovarian cancer treatment. J Clin Oncol. 2007;25:2884-2893. (Pubitemid 47123152)
41. Coukos G, Conejo-Garcia JR, Roden RB, Wu TC. Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther. 2005;5:1193-1210. (Pubitemid 41243355)
42. Chu CS, Kim SH, June CH, Coukos G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther. 2008;8:243-257.